Back to Search Start Over

Home-based intravenous treatment with reslizumab for severe asthma in the Netherlands - An evaluation.

Authors :
Bendien SA
van Leeuwen MM
Lau HS
Ten Brinke A
Visser LE
de Koning EM
Braunstahl GJ
Source :
Respiratory medicine [Respir Med] 2022 Apr; Vol. 194, pp. 106776. Date of Electronic Publication: 2022 Feb 23.
Publication Year :
2022

Abstract

The anti-IL-5 biologic reslizumab for the treatment of severe eosinophilic asthma is administered intravenously. In the current study home administration of intravenous reslizumab was evaluated in 24 patients included between 2019 (July) and 2020 (July). This is the first study to show that intravenous reslizumab can be administered safely and successfully in an outpatient setting. Notably, not all patients prefer home administration and severe asthma patients may have different needs when it comes to choosing treatment at home or in the hospital.<br /> (Copyright © 2022 Elsevier Ltd. All rights reserved.)

Details

Language :
English
ISSN :
1532-3064
Volume :
194
Database :
MEDLINE
Journal :
Respiratory medicine
Publication Type :
Academic Journal
Accession number :
35221150
Full Text :
https://doi.org/10.1016/j.rmed.2022.106776